CR9232A - Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas - Google Patents

Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas

Info

Publication number
CR9232A
CR9232A CR9232A CR9232A CR9232A CR 9232 A CR9232 A CR 9232A CR 9232 A CR9232 A CR 9232A CR 9232 A CR9232 A CR 9232A CR 9232 A CR9232 A CR 9232A
Authority
CR
Costa Rica
Prior art keywords
diagnosis
proliferative diseases
cyanine
colors
cyanine colors
Prior art date
Application number
CR9232A
Other languages
English (en)
Inventor
Kai Licha
Martin Pessel
Malte Bahner
Michael Schirner
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9232(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9232A publication Critical patent/CR9232A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere al uso del colorante de cianina SF64 para el diagnostico de enfermedades proliferativas con una administracion que comprende menos que 5 mg/kg de peso corporal.
CR9232A 2005-01-07 2007-07-06 Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas CR9232A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05000276A EP1679082A1 (en) 2005-01-07 2005-01-07 Use of cyanine dyes for the diagnosis of proliferative diseases

Publications (1)

Publication Number Publication Date
CR9232A true CR9232A (es) 2007-11-23

Family

ID=34933224

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9232A CR9232A (es) 2005-01-07 2007-07-06 Uso de colorantes de cianina para el diagnostico de enfermedades proliferativas

Country Status (23)

Country Link
EP (2) EP1679082A1 (es)
JP (1) JP5578765B2 (es)
KR (1) KR20070092270A (es)
CN (1) CN101128218A (es)
AR (1) AR052190A1 (es)
AU (1) AU2006204496A1 (es)
BR (1) BRPI0606411A2 (es)
CA (1) CA2594390C (es)
CR (1) CR9232A (es)
DO (1) DOP2006000005A (es)
GT (1) GT200600001A (es)
IL (1) IL182499A0 (es)
MX (1) MX2007008300A (es)
NO (1) NO20074036L (es)
NZ (1) NZ554917A (es)
PA (1) PA8659101A1 (es)
PE (2) PE20060872A1 (es)
RU (1) RU2007129919A (es)
TW (1) TW200635612A (es)
UA (1) UA89976C2 (es)
UY (1) UY29323A1 (es)
WO (1) WO2006072580A1 (es)
ZA (1) ZA200706533B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1619501B1 (en) * 2004-07-22 2007-09-26 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1743658A1 (en) * 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
CA2681790A1 (en) * 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
WO2009152440A1 (en) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
EP2459053A2 (en) 2009-07-28 2012-06-06 F. Hoffmann-La Roche AG Non-invasive in vivo optical imaging method
DK2470887T3 (da) 2009-08-28 2020-04-06 Visen Medical Inc Systemer til tomografisk billeddannelse i diffuse medier ved at anvende en hybrid inversionsteknik
JP2011046662A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
JP2011046663A (ja) * 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
EP2480126B1 (en) 2009-09-22 2017-01-04 VisEn Medical, Inc. Systems and methods for virtual index-matching of diffusive media
RU2012148816A (ru) 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
JP6100704B2 (ja) 2011-03-07 2017-03-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療用抗体についてのインビボ試験の手段および方法
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
KR101373108B1 (ko) 2012-01-20 2014-03-27 이화여자대학교 산학협력단 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법
CN102608051B (zh) * 2012-02-21 2015-04-08 中国科学院化学研究所 用于诊断白血病的试剂盒
CN102703569B (zh) * 2012-05-24 2014-04-09 中国科学院化学研究所 菁染料的新用途
CN102706787B (zh) * 2012-05-24 2015-04-08 中国科学院化学研究所 菁染料的新用途
CN104853669B (zh) 2012-10-15 2017-07-21 文森医学公司 具有荧光及生物发光源的交叉形态加权特征的漫射介质成像的系统、方法及设备
JP6384821B2 (ja) * 2012-10-26 2018-09-05 国立大学法人三重大学 がん細胞阻害薬、がん幹細胞検出用プローブ
WO2014092958A1 (en) * 2012-12-10 2014-06-19 Molecular Targeting Technologies, Inc. Compositions and methods of diagnosing ocular diseases
CN113349707A (zh) 2013-12-31 2021-09-07 纪念斯隆-凯特琳癌症中心 用于荧光源实时多通道成像的系统、方法和设备
RU2565645C1 (ru) * 2014-09-05 2015-10-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани
ES2794778T3 (es) 2014-12-15 2020-11-19 Memorial Sloan Kettering Cancer Center Péptidos cíclicos con selectividad mejorada de unión a los nervios, nanoparticulos unidas con dichos péptidos cíclicos y uso de los mismos para imágenes en vivo de tejidos nerviosos en tiempo real
JP2019509252A (ja) 2015-12-15 2019-04-04 メモリアル スローン ケタリング キャンサー センター 組織の区別、例えば、手術中の可視化のための、イメージングシステムおよび方法
EP3548096B1 (en) 2016-11-30 2024-11-20 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
US11989803B2 (en) 2018-03-30 2024-05-21 Perkinelmer Health Sciences, Inc. Systems and methods for 3D reconstruction of anatomical organs and inclusions using short-wave infrared (SWIR) projection tomography
JP2022053289A (ja) * 2020-09-24 2022-04-05 大塚製薬株式会社 シアニン系色素、標識試薬および検出方法
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
BR0318028A (pt) * 2003-01-24 2005-12-06 Schering Ag Corantes hidrofìlicos de cianina reativos a tiol e conjugados dos mesmos com biomoléculas para diagnóstico por fluorescência
EP1619501B1 (en) * 2004-07-22 2007-09-26 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
CA2594390C (en) 2013-10-22
EP1679082A1 (en) 2006-07-12
AU2006204496A1 (en) 2006-07-13
RU2007129919A (ru) 2009-02-20
EP1833513A1 (en) 2007-09-19
PE20060872A1 (es) 2006-10-01
AR052190A1 (es) 2007-03-07
JP2008526802A (ja) 2008-07-24
TW200635612A (en) 2006-10-16
IL182499A0 (en) 2007-09-20
PA8659101A1 (es) 2006-09-08
NZ554917A (en) 2010-01-29
DOP2006000005A (es) 2006-07-15
CA2594390A1 (en) 2006-07-13
CN101128218A (zh) 2008-02-20
PE20100449A1 (es) 2010-07-25
BRPI0606411A2 (pt) 2009-06-23
NO20074036L (no) 2007-08-03
UY29323A1 (es) 2006-10-02
JP5578765B2 (ja) 2014-08-27
WO2006072580A1 (en) 2006-07-13
MX2007008300A (es) 2007-09-07
KR20070092270A (ko) 2007-09-12
UA89976C2 (ru) 2010-03-25
EP1833513B1 (en) 2013-03-06
GT200600001A (es) 2006-08-22
ZA200706533B (en) 2009-07-29

Similar Documents

Publication Publication Date Title
UY29323A1 (es) Uso de colorantes de cianina para el dignostico de enfermedades proliferativas
ECSP21078204A (es) Compuestos y conjugados de estos
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
AR062448A1 (es) Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
HN2008000360A (es) Dispersiones amorfas solidas
BR112015022015A2 (pt) veículo utilitário
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
PA8599401A1 (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
PA8740901A1 (es) Compuestos organicos
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
CR10842A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
GT200400257A (es) Composicion herbicida
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
AR057239A1 (es) Inmunoglobulinas
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)